Skip to main content

Table 1 Baseline characteristics of patients

From: Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

N ATG PTCY Test p value
1452 174  
Follow-up
 Median time (IQR) mo 33.2 (17.6–52.7) 20.5 (6.9–32.6) < 0.001
Age at allo-HSCT
 Median (range) [IQR] 56 (18.1–77.5) [44.3–62.6] 46 (18–74.2) [34.7–59.3] < 0.001
Year allo-HSCT
 Median (range) [IQR] 2014 (2010–2017) 2016 (2010–2017) < 0.001
Time diagnosis to allo-HSCT
 Median (range) [IQR] 5.4 (1.5–17.7) [4.4–6.6] 4.7 (1.8–17.9) [3.8–7.7] 0.1
AML
 De novo 1206 (83.06%) 161 (92.53%) 0.001
 secAML 246 (16.94%) 13 (7.47%)
Cytogenetics (MRC)
 Good 59 (4.06%) 4 (2.3%) 0.19
 Interm 740 (50.96%) 80 (45.98%)
 Poor 291 (20.04%) 35 (20.11%)
 NA/failed 362 (24.93%) 55 (31.61%)
Conditioning regimen
 MAC 687 (47.31%) 76 (43.68%) 0.36
 RIC 765 (52.69%) 98 (56.32%)
Gaft cell type
 BM 143 (9.85%) 18 (10.34%) 0.84
 PBSC 1309 (90.15%) 156 (89.66%)
Kanofsky performance score
 < 90 331 (24.68%) 29 (16.76%) 0.02
 ≥ 90 1010 (75.32%) 144 (83.24%)
 Missing 111 1
Patient sex
 Male 759 (52.27%) 98 (56.32%) 0.31
 Female 693 (47.73%) 76 (43.68%)
Female donor-male recipient 165 (11.41%) 26 (14.94%) 0.17
Patient CMV serostatus
 Negative 499 (34.92%) 43 (25.15%) 0.011
 Positive 930 (65.08%) 128 (74.85%)
 Missing 23 3
Engraftement
 Graft failure 12 (0.83%) 2 (1.16%) 0.65
 Engrafted 1432 (99.17%) 170 (98.84%)
 Missing 8 2
  1. Abbreviations: allo-HSCT allogeneic stem cell transplantation, AML acute myeloid leukemia, ATG anti-thymocyte globulin, BM bone marrow, CMV cytomegalovirus, Interm intermediary, IQR interquartile range, KPS Karnovsky Performance Status, MAC myeloablative conditioning regimen, PBSC peripheral blood stem cell, PTCY posttransplantation cyclophosphamide, RIC reduced intensity conditioning regimen, secAML secondary acute myeloid leukemia